The Medical Equipment and Supplies industry within the Health Care sector sees positive seasonal strengths around this time of year. Neogen is a company that operates within this space, developing, manufacturing and marketing a line of products dedicated to food and animal safety. Does this stock have what is takes to safely provide returns to your portfolio?
Of the 1651 stocks analyzed on Wednesday, a whopping 1600 advanced, 47 declined and the remaining 4 stepped out for the day. Gains across the stocks averaged an astounding 3.81% on volumes 23% lower than the day previous. Looking at the capitalizations, returns averaged 3.63%, 4.06% and 4.20% for Large-caps, Mid-caps, and Small-Caps, respectively. Thursday saw a huge improvement to the percentage of stocks above the 50-day moving average, now at 24% above this critical level.
Analysis has revealed that with a buy date of March 12 and a sell date of December 28, investors have benefited from a total return of 1773.36% over the last 10 years.This scenario has shown positive results in 8 of those periods.
The buy and hold return for the past 10 years was 1162.57%.
Comments:
This stock currently has an analyst outperform rating and institutions have been witnessed accumulating shares on net.The stock currently has a low beta of 0.65, allowing enough movement for upside returns, yet cushioning returns from volatility.Company fundamentals seem reasonable and place a value on this stock of $28.60.The stock is currently in a long-term uptrend since the March 2009 bottom, not impacted to any great extent by the recent market downturn. The charts show a strong seasonal uptrend in this equity from mid-June through to October for gains surpassing 15%, on average.
Equity Clock – By The Numbers will be offered following each trading day.
Disclosure: Mr. Vialoux does not own securities mentioned in this report.
Disclaimer: Comments and opinions offered in this report at EquityClock.com are for information only. They should not be considered as advice to purchase or to sell mentioned securities.
Data offered in this report is believed to be accurate, but is not guaranteed.
Click Here to learn more about the proprietary, seasonal rotation investment strategy developed by research analysts Don Vialoux, Brooke Thackray, and Jon Vialoux.
